Cargando…

Thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery

The thiazolidinediones (TZDs) are used in the treatment of diabetes mellitus type 2. Their canonical effects are mediated by activation of the peroxisome proliferator–activated receptor γ (PPARγ) transcription factor. In addition to effects mediated by gene activation, the TZDs cause acute, transcri...

Descripción completa

Detalles Bibliográficos
Autores principales: Rusinova, Radda, Herold, Karl F., Sanford, R. Lea, Greathouse, Denise V., Hemmings, Hugh C., Andersen, Olaf S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149818/
https://www.ncbi.nlm.nih.gov/pubmed/21788612
http://dx.doi.org/10.1085/jgp.201010529
_version_ 1782209492732084224
author Rusinova, Radda
Herold, Karl F.
Sanford, R. Lea
Greathouse, Denise V.
Hemmings, Hugh C.
Andersen, Olaf S.
author_facet Rusinova, Radda
Herold, Karl F.
Sanford, R. Lea
Greathouse, Denise V.
Hemmings, Hugh C.
Andersen, Olaf S.
author_sort Rusinova, Radda
collection PubMed
description The thiazolidinediones (TZDs) are used in the treatment of diabetes mellitus type 2. Their canonical effects are mediated by activation of the peroxisome proliferator–activated receptor γ (PPARγ) transcription factor. In addition to effects mediated by gene activation, the TZDs cause acute, transcription-independent changes in various membrane transport processes, including glucose transport, and they alter the function of a diverse group of membrane proteins, including ion channels. The basis for these off-target effects is unknown, but the TZDs are hydrophobic/amphiphilic and adsorb to the bilayer–water interface, which will alter bilayer properties, meaning that the TZDs may alter membrane protein function by bilayer-mediated mechanisms. We therefore explored whether the TZDs alter lipid bilayer properties sufficiently to be sensed by bilayer-spanning proteins, using gramicidin A (gA) channels as probes. The TZDs altered bilayer elastic properties with potencies that did not correlate with their affinity for PPARγ. At concentrations where they altered gA channel function, they also altered the function of voltage-dependent sodium channels, producing a prepulse-dependent current inhibition and hyperpolarizing shift in the steady-state inactivation curve. The shifts in the inactivation curve produced by the TZDs and other amphiphiles can be superimposed by plotting them as a function of the changes in gA channel lifetimes. The TZDs’ partition coefficients into lipid bilayers were measured using isothermal titration calorimetry. The most potent bilayer modifier, troglitazone, alters bilayer properties at clinically relevant free concentrations; the least potent bilayer modifiers, pioglitazone and rosiglitazone, do not. Unlike other TZDs tested, ciglitazone behaves like a hydrophobic anion and alters the gA monomer–dimer equilibrium by more than one mechanism. Our results provide a possible mechanism for some off-target effects of an important group of drugs, and underscore the importance of exploring bilayer effects of candidate drugs early in drug development.
format Online
Article
Text
id pubmed-3149818
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-31498182012-02-01 Thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery Rusinova, Radda Herold, Karl F. Sanford, R. Lea Greathouse, Denise V. Hemmings, Hugh C. Andersen, Olaf S. J Gen Physiol Article The thiazolidinediones (TZDs) are used in the treatment of diabetes mellitus type 2. Their canonical effects are mediated by activation of the peroxisome proliferator–activated receptor γ (PPARγ) transcription factor. In addition to effects mediated by gene activation, the TZDs cause acute, transcription-independent changes in various membrane transport processes, including glucose transport, and they alter the function of a diverse group of membrane proteins, including ion channels. The basis for these off-target effects is unknown, but the TZDs are hydrophobic/amphiphilic and adsorb to the bilayer–water interface, which will alter bilayer properties, meaning that the TZDs may alter membrane protein function by bilayer-mediated mechanisms. We therefore explored whether the TZDs alter lipid bilayer properties sufficiently to be sensed by bilayer-spanning proteins, using gramicidin A (gA) channels as probes. The TZDs altered bilayer elastic properties with potencies that did not correlate with their affinity for PPARγ. At concentrations where they altered gA channel function, they also altered the function of voltage-dependent sodium channels, producing a prepulse-dependent current inhibition and hyperpolarizing shift in the steady-state inactivation curve. The shifts in the inactivation curve produced by the TZDs and other amphiphiles can be superimposed by plotting them as a function of the changes in gA channel lifetimes. The TZDs’ partition coefficients into lipid bilayers were measured using isothermal titration calorimetry. The most potent bilayer modifier, troglitazone, alters bilayer properties at clinically relevant free concentrations; the least potent bilayer modifiers, pioglitazone and rosiglitazone, do not. Unlike other TZDs tested, ciglitazone behaves like a hydrophobic anion and alters the gA monomer–dimer equilibrium by more than one mechanism. Our results provide a possible mechanism for some off-target effects of an important group of drugs, and underscore the importance of exploring bilayer effects of candidate drugs early in drug development. The Rockefeller University Press 2011-08 /pmc/articles/PMC3149818/ /pubmed/21788612 http://dx.doi.org/10.1085/jgp.201010529 Text en © 2011 Rusinova et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
spellingShingle Article
Rusinova, Radda
Herold, Karl F.
Sanford, R. Lea
Greathouse, Denise V.
Hemmings, Hugh C.
Andersen, Olaf S.
Thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery
title Thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery
title_full Thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery
title_fullStr Thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery
title_full_unstemmed Thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery
title_short Thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery
title_sort thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149818/
https://www.ncbi.nlm.nih.gov/pubmed/21788612
http://dx.doi.org/10.1085/jgp.201010529
work_keys_str_mv AT rusinovaradda thiazolidinedioneinsulinsensitizersalterlipidbilayerpropertiesandvoltagedependentsodiumchannelfunctionimplicationsfordrugdiscovery
AT heroldkarlf thiazolidinedioneinsulinsensitizersalterlipidbilayerpropertiesandvoltagedependentsodiumchannelfunctionimplicationsfordrugdiscovery
AT sanfordrlea thiazolidinedioneinsulinsensitizersalterlipidbilayerpropertiesandvoltagedependentsodiumchannelfunctionimplicationsfordrugdiscovery
AT greathousedenisev thiazolidinedioneinsulinsensitizersalterlipidbilayerpropertiesandvoltagedependentsodiumchannelfunctionimplicationsfordrugdiscovery
AT hemmingshughc thiazolidinedioneinsulinsensitizersalterlipidbilayerpropertiesandvoltagedependentsodiumchannelfunctionimplicationsfordrugdiscovery
AT andersenolafs thiazolidinedioneinsulinsensitizersalterlipidbilayerpropertiesandvoltagedependentsodiumchannelfunctionimplicationsfordrugdiscovery